AlloVir (ALVR) Competitors $2.46 -0.11 (-4.28%) As of 08/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVR vs. COEP, STTK, KLRS, VTVT, LTRN, KPTI, IPSC, BRNS, EQ, and ATHEShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Coeptis Therapeutics (COEP), Shattuck Labs (STTK), Kalaris Therapeutics (KLRS), vTv Therapeutics (VTVT), Lantern Pharma (LTRN), Karyopharm Therapeutics (KPTI), Century Therapeutics (IPSC), Barinthus Biotherapeutics (BRNS), Equillium (EQ), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Its Competitors Coeptis Therapeutics Shattuck Labs Kalaris Therapeutics vTv Therapeutics Lantern Pharma Karyopharm Therapeutics Century Therapeutics Barinthus Biotherapeutics Equillium Alterity Therapeutics AlloVir (NASDAQ:ALVR) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation. Do institutionals & insiders believe in ALVR or COEP? 66.1% of AlloVir shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ALVR or COEP more profitable? AlloVir's return on equity of -71.03% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AlloVirN/A -71.03% -61.27% Coeptis Therapeutics N/A -201.73%-108.46% Which has more risk and volatility, ALVR or COEP? AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.59, indicating that its share price is 159% less volatile than the S&P 500. Does the media prefer ALVR or COEP? In the previous week, Coeptis Therapeutics had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Coeptis Therapeutics and 0 mentions for AlloVir. Coeptis Therapeutics' average media sentiment score of 1.95 beat AlloVir's score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment AlloVir Neutral Coeptis Therapeutics Very Positive Which has higher valuation & earnings, ALVR or COEP? Coeptis Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlloVirN/AN/A-$190.42M-$20.23-0.12Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.32 SummaryAlloVir beats Coeptis Therapeutics on 6 of the 10 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.41M$283.36M$5.76B$9.58BDividend YieldN/AN/A4.41%4.10%P/E Ratio-0.12N/A31.1026.05Price / SalesN/A563.89432.51103.82Price / CashN/A22.4437.7358.48Price / Book0.0810.439.536.61Net Income-$190.42M-$115.81M$3.26B$265.56M7 Day PerformanceN/A-0.72%2.10%1.97%1 Month Performance-4.28%-6.95%2.81%-0.36%1 Year Performance-85.74%-8.54%30.56%19.03% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$2.46-4.3%N/A-86.0%$12.41MN/A-0.12110COEPCoeptis Therapeutics0.7259 of 5 stars$14.24-2.9%N/A+228.9%$49.99MN/A-2.462News CoveragePositive NewsShort Interest ↑STTKShattuck Labs3.5432 of 5 stars$1.05+2.5%$7.00+569.9%-70.6%$49.58M$5.72M-0.86100News CoverageKLRSKalaris Therapeutics1.3206 of 5 stars$2.64+5.6%$3.00+13.6%N/A$49.37MN/A0.00110Gap UpVTVTvTv Therapeutics1.6245 of 5 stars$15.38-0.4%$35.50+130.9%-8.4%$49.12M$17K-4.939Gap DownHigh Trading VolumeLTRNLantern Pharma2.7017 of 5 stars$4.55+2.4%$25.00+450.1%+6.9%$49.09MN/A-2.5520Positive NewsKPTIKaryopharm Therapeutics3.922 of 5 stars$5.61+0.4%$34.00+506.1%-46.6%$48.69M$137.27M-0.38380IPSCCentury Therapeutics3.0337 of 5 stars$0.57-1.5%$3.75+562.5%-69.1%$48.68M$6.59M-1.95170Analyst RevisionBRNSBarinthus Biotherapeutics3.2374 of 5 stars$1.20+0.4%$3.00+151.0%-4.8%$48.21M$14.97M-0.69107Short Interest ↑EQEquillium0.9699 of 5 stars$1.31-2.2%$1.00-23.7%+102.2%$47.69M$41.10M-2.3840Gap DownATHEAlterity Therapeutics2.2389 of 5 stars$5.27+0.3%$12.00+127.9%+280.3%$46.70MN/A0.0010 Related Companies and Tools Related Companies COEP Alternatives STTK Alternatives KLRS Alternatives VTVT Alternatives LTRN Alternatives KPTI Alternatives IPSC Alternatives BRNS Alternatives EQ Alternatives ATHE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access